Vanda Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell VNDA and other ETFs, options, and stocks.

About VNDA

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. 

CEO
Mihael Hristos Polymeropoulos
CEOMihael Hristos Polymeropoulos
Employees
368
Employees368
Headquarters
Washington, District of Columbia
HeadquartersWashington, District of Columbia
Founded
2002
Founded2002
Employees
368
Employees368

VNDA Key Statistics

Market cap
307.30M
Market cap307.30M
Price-Earnings ratio
-3.63
Price-Earnings ratio-3.63
Dividend yield
Dividend yield
Average volume
709.15K
Average volume709.15K
High today
$6.09
High today$6.09
Low today
$5.18
Low today$5.18
Open price
$5.25
Open price$5.25
Volume
958.93K
Volume958.93K
52 Week high
$6.09
52 Week high$6.09
52 Week low
$3.81
52 Week low$3.81

Stock Snapshot

Vanda Pharmaceuticals(VNDA) stock is priced at $5.58, giving the company a market capitalization of 307.3M. It carries a P/E multiple of -3.63.

On 2025-12-05, Vanda Pharmaceuticals(VNDA) stock traded between a low of $5.18 and a high of $6.09. Shares are currently priced at $5.58, which is +7.8% above the low and -8.4% below the high.

The Vanda Pharmaceuticals(VNDA)'s current trading volume is 958.93K, compared to an average daily volume of 709.15K.

During the past year, Vanda Pharmaceuticals(VNDA) stock moved between $3.81 at its lowest and $6.09 at its peak.

During the past year, Vanda Pharmaceuticals(VNDA) stock moved between $3.81 at its lowest and $6.09 at its peak.

VNDA News

TipRanks 8h
FDA Lifts Hold on Vanda’s Tradipitant Trials

TipRanks Cyber Monday Sale Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRank...

TipRanks 9h
FDA lifts partial clinical hold on Vanda Pharmaceuticals’ tradipitant

Vanda Pharmaceuticals (VNDA) announced that the FDA has lifted the partial clinical hold on protocol VP-VLY-686-3403, which until today limited the protocol to...

The Motley Fool 5d
Should You Invest in This Under-the-Radar Weight Loss Stock?

This small-cap drugmaker just soared on positive clinical trial data, but should you jump on the bandwagon? The weight loss market has become one of the hottes...

Should You Invest in This Under-the-Radar Weight Loss Stock?

More VNDA News

Benzinga 7d
FDA Fast-Tracks Vanda's Motion Sickness Drug Review After Leadership Shake-Up

On Friday, Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) announced the U.S. Food and Drug Administration (FDA) is conducting an expedited re-review of the partial cl...

FDA Fast-Tracks Vanda's Motion Sickness Drug Review After Leadership Shake-Up

People also own

Based on the portfolios of people who own VNDA. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.